{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:41:38Z","timestamp":1793173298421,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T00:00:00Z","timestamp":1171929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective:\u2002<\/jats:bold> Myelodysplastic syndromes (MDS) and aplastic anemia (AA) are the most common anemias that require transfusion therapy in Japan. This retrospective survey investigated relationships between iron overload, chelation practices, and morbidity\/mortality in patients with these diseases.<\/jats:p><jats:p><jats:bold>Method:\u2002<\/jats:bold> Medical histories of transfusion\u2010dependent patients were assessed at transfusion onset, chelation onset, and study end.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Data were collected from 292 patients with MDS, AA, pure red cell aplasia, myelofibrosis, and other conditions. Patients received a mean of 61.5 red blood cell units during the previous year. Fewer than half (43%) of patients had previously received deferoxamine (DFO) therapy. Only 8.6% received daily\/continuous DFO. In all, 75 deaths were reported, with cardiac and liver failure noted in 24.0 and 6.7% of cases. Of these, 97% had ferritin levels &gt;1000\u2003ng\/mL. Abnormal cardiac and liver function was observed in 21.9% (14\/64) and 84.6% (11\/13) of all patients assessed. Effective chelation with DFO resulted in improved serum ferritin, liver enzymes, and fasting blood sugar.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Mortality is higher in heavily iron\u2010overloaded patients, with liver and cardiac dysfunction being the primary cause. Daily\/continuous chelation therapy was effective at reducing iron burden and improving organ function. Chelation therapy should be initiated once serum ferritin levels exceed 1000\u2003ng\/mL.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2007.00842.x","type":"journal-article","created":{"date-parts":[[2007,3,28]],"date-time":"2007-03-28T10:35:35Z","timestamp":1175078135000},"page":"487-494","source":"Crossref","is-referenced-by-count":173,"title":["Retrospective nationwide survey of Japanese patients with transfusion\u2010dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality"],"prefix":"10.1111","volume":"78","author":[{"given":"Masaaki","family":"Takatoku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tomonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsutoshi","family":"Nakahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Murate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,2,20]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"Japan Intractable Diseases Information Center. Available at:http:\/\/www.nanbyou.or.jp."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80131-3"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408368309165764"},{"key":"e_1_2_7_5_2","volume-title":"Hematology\/American Society of Hematology Education Program Book","author":"Kushner JP","year":"2001"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1980.tb33678.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840060106"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250130"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.63.1.58"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2002.0320s1070.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/3.6.1127"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2006.0007"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03907.x"},{"key":"e_1_2_7_14_2","first-page":"1286","article-title":"Evidence\u2010 and consensus\u2010based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology","volume":"7","author":"Alessandrino EP","year":"2002","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_7_15_2","first-page":"18","article-title":"Consensus statement on iron overload in myelodysplastic syndromes","volume":"19","author":"Gattermann N","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.7038"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198506203122503"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1985.tb17198.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb55509.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.1994.tb02592.x"},{"key":"e_1_2_7_21_2","volume-title":"Guidelines for the Clinical Management of Thalassaemia","author":"Thalassaemia International Federation","year":"2002"},{"key":"e_1_2_7_22_2","volume-title":"Clinical Practice Guidelines in Oncology","author":"National Comprehensive Cancer Network","year":"2006"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02357-6"},{"key":"e_1_2_7_24_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1182\/blood.V108.11.249.249","article-title":"Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy","volume":"108","author":"Leitch HA","year":"2006","journal-title":"Blood"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203853"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310902"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1795.x"},{"key":"e_1_2_7_28_2","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once\u2010daily, orally\u2010administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"e_1_2_7_30_2","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood.V104.11.3193.3193","article-title":"A phase II study with ICL670 (Exjade\u00ae), a once\u2010daily oral iron chelator, in patients with various transfusion\u2010dependent anemias and iron overload","volume":"104","author":"Porter J","year":"2004","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2007.00842.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2007.00842.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:53:48Z","timestamp":1696967628000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2007.00842.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,20]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1111\/j.1600-0609.2007.00842.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00842.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,20]]}}}